Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RVNC—JP Morgan increases its stake to 12% from 10.4% a year ago.
http://www.conferencecalltranscripts.org/13G/summary2/?id=3382480
via Insidercow:
http://206.222.29.162/institution/subject.jsp?subject=0001479290&company=RVNC
It does. It was running too fast and the low float of 2M OS works both ways.
Biotech Showcase Webcast at 2:30pm ET (11:30am PT)
https://event.webcasts.com/starthere.jsp?ei=1130360
SGNL +177%; special meeting to vote on merger with Miragen
https://biz.yahoo.com/e/170109/sgnl8-k.html
On January 9, 2017, Signal Genetics, Inc. ("Signal") issued a press release announcing that it has set a date for a special meeting of its stockholders to vote on matters related to the previously announced proposed merger with Miragen Therapeutics, Inc. ("Miragen") and the sale of Signal's MyPRS intellectual property assets. The special meeting will be held at 9:00 a.m., local time, on February 10, 2017 at 12255 El Camino Real, Suite 300, San Diego, California 92130. Signal stockholders of record as of the close of business on January 9, 2017 are entitled to receive notice of, and to vote at, the special meeting.
Thanks jbog, I stand corrected.
Agreed, as the gains have come after the R/S. I suspect an offering must be on its way soon.
No position.
ETRM +58%; +1,400% in 2017; currently trading at $28.16
All these gains have come after the 1:10 R/S in December 2016.
SRPT opens up about Duchenne drug launch, allays investors' worst fears
https://www.thestreet.com/story/13948568/1/sarepta-opens-up-about-duchenne-drug-launch-allays-investors-worst-fears.html
Sarepta Therapeutics (SRPT) is providing two numbers Tuesday that should wipe away the worst fears investors have had about the commercial launch of Exondys 51, its newly approved treatment for boys with Duchenne muscular dystrophy (DMD.).
In the fourth quarter, Sarepta recorded $5.4 million in sales of Exondys 51, the company said. The drug was approved on Sept. 19.
Street expectations for Exondys 51 sales in its first quarter of commercial launch have been volatile and widely divergent but the analyst consensus was $4.9 million, according to Factset.
Relevant but not directly related...
Molecular Med Tri-Con 2017
IMMUNOSEQUENCING AND CANCER MEDICINE
Profiling of Exhausted T Cells in Tumors Predicts PD-1 Response
Adil Daud, M.D., HS Clinical Professor, Medicine (Hematology/Oncology); Director, Melanoma Clinical Research, Helen Diller Comprehensive Cancer Center, University of California, San Francisco
Immune checkpoint blockade is revolutionizing therapy for advanced cancer. However, many patients do not respond to treatment. The identification of robust biomarkers that predict clinical response to specific checkpoint inhibitors is critical in order to stratify patients and to rationally select combinations in the context of an expanding array of therapeutic options. We performed multi-parameter flow cytometry on freshly isolated metastatic melanoma samples prior to treatment and correlated subsequent clinical response with tumor immune phenotype.
http://www.triconference.com/Personalized-Diagnostics/
Here's a Biotech IPO You'll Want to Watch [Jounce Therapeutics; MRK, BMY, CELG]
http://www.fool.com/investing/2017/01/09/heres-a-biotech-ipo-youll-want-to-watch.aspx
Jounce has a grand total of one candidate in clinical testing -- experimental cancer drug JTX-2011. And it's only in early-stage development. JTX-2011 has enough potential, though, that Celgene paid the small biotech $225 million up front and bought a $36 million stake in the company. The deal also includes an option for Celgene to license up to four other immunotherapies.
Mysterious $5 Billion Biotech Firm Moderna Lays Out Drug Pipeline
http://www.forbes.com/sites/matthewherper/2017/01/09/mysterious-5-billion-biotech-firm-moderna-lays-out-drug-pipeline/#578382774078
DARPA's Biotech Chief Says 2017 Will "Blow Our Minds"
https://www.scientificamerican.com/article/darpa-rsquo-s-biotech-chief-says-2017-will-ldquo-blow-our-minds-rdquo/?wt.mc=SA_Twitter-Share #science
Interesting story on BBC News - 'Tooth repair drug' may replace fillings
http://www.bbc.com/news/uk-38524566
Teeth can be encouraged to repair themselves in a way that could see an end to fillings, say scientists.
The team at King's College London showed that a chemical could encourage cells in the dental pulp to heal small holes in mice teeth.
A biodegradable sponge was soaked in the drug and then put inside the cavity.
The study, published in Science Reports, showed it led to "complete, effective natural repair".
This makes me feel good about what may come in the near future.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=126692360
Establishment and management of corporate alliances in three broad areas:
1) Partnering of lead program toward registration trial in melanoma
2) Partnering of lead program in follow-on indications globally
3) Partnering of technology and pipeline projects
Establishment of preclinical fee-for-service tech access program
Amgen, Sanofi and Merck announce a string of deals at #JPM17
https://endpts.com/amgen-sanofi-and-merck-announce-a-string-of-deals-at-jpm17
• Amgen has tied the knot with Germany’s Immatics, paying $30 million upfront and offering hundreds of millions more in possible milestones for the development of bispecific T cell-engaging therapeutics for a range of cancers.
• Just weeks after ImmuNext signed Roche up as a partner, Sanofi has stepped on board to partner on a preclinical CD40L antibody for autoimmune disease that has potential in treating multiple sclerosis and lupus. The deal is worth a potential $500 million, though it likely starts out on the small side.
• Incyte and Merck are kicking off a slate of new pivotal studies for their combination of Keytruda and the IDO1 inhibitor epacadostat. They are expanding their pact to include non-small cell lung cancer, renal cell carcinoma, bladder cancer and squamous cell carcinoma of the head and neck.
Sabby Healthcare Master Fund, Ltd. just provided an update on share ownership of ONCOSEC MEDICAL Inc
http://www.conferencecalltranscripts.org/13G/summary/?id=3375610
EXAS (+15% /PM) on higher revenues
Exact Sciences (EXAS) Sees Q4 Revs of $34.9-$35.4M, Vs. Consensus of $30.15M http://www.streetinsider.com/Corporate+News/Exact+Sciences+%28EXAS%29+Sees+Q4+Revs+of+%2434.9-%2435.4M%2C+Vs.+Consensus+of+%2430.15M/12405347.html
For the full-year 2016, the company anticipates revenues between $99.0 million and $99.5 million, a year-over-year increase of 150 percent. Completed Cologuard test volume during 2016 was approximately 244,000 tests, a 134-percent increase from 2015.
Takeda will probably be looking to do additional deals this year. From last year:
Takeda earmarks $15bn for US pharmaceutical acquisitions
https://www.ft.com/content/5c8e5c50-79c5-11e6-97ae-647294649b28
The drugmaker, Japan’s biggest by market value, has told investors it wants to buy US companies developing drugs for cancer, gastrointestinal conditions and diseases of the central nervous system, such as Alzheimer’s, the people said.
The company has set aside $10bn to $15bn for acquisitions, which could go towards one large deal or several smaller ones, the people said. One investor in Takeda said the group had said it could stretch to $20bn for the right assets.
MACK - France's Ipsen to buy some Merrimack assets for up to $1 billion
http://reut.rs/2i5ICH4
French drugmaker Ipsen SA (IPN.PA) said on Monday it would buy some assets of U.S. peer Merrimack Pharmaceuticals Inc (MACK.O), including its pancreatic cancer treatment Onivyde, for up to $1 billion.
Ipsen will pay $575 million at the closing of the deal and up to $450 million more, contingent on some approvals for Onivyde in the United States.
The deal would give Merrimack the resources to fund the development of three new compounds targeting pancreatic, lung, and other types of cancers. It would boost Ipsen's portfolio, which has traditionally focused on endocrinology.
Ipsen will get exclusive commercialization rights for Onivyde in the United States, the current licensing agreements with Shire Plc (SHP.L) for commercialization rights excluding the United States and with PharmaEngine Inc (4162.TWO) for Taiwan.
Another good day. Looks like a reversal is in order.
XXII - Got out at $1.02 this morning. I was surprised it didn't open lower. I think this sets the clock back by at least a year and a few months.
Pierce appointed to Immunomic's scientific advisory board
http://www.businesswire.com/news/home/20170105005173/en/Immunomic-Therapeutics-Announces-Scientific-Advisory-Board-Additions
I had a small position back in 2012 when perifosine failed phase 3 for colon cancer. There have been two reverse splits since then if I'm not wrong. I might just stay out.
Any thoughts on the prospects of its upcoming Zoptrex phase 3 data Dew?
http://www.businesswire.com/news/home/20160606006290/en/Aeterna-Zentaris-Reconfirms-Commitment-LHRH-receptor-Targeting-Zoptrex%E2%84%A2
AEZS had been on my watch list. Glad I didn't get in. Considering getting a small speculative position for Zoptrex though.
This looks like one of those "stock alert" template reports where they just fill the relevant metrics for a given ticker and mash up an article. I don't believe this is ONCS-sponsored. ONCS would more likely sponsor something like the LifeSci report which has some detailed analysis and effort put into it.
Interpace Diagnostics Announces $4.2 Million Registered Direct Offering of Common Stock
http://www.prnewswire.com/news-releases/interpace-diagnostics-announces-42-million-registered-direct-offering-of-common-stock-300384916.html
PARSIPPANY, N.J., Jan. 3, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)("Interpace" or the "Company"), a company that provides clinically useful molecular diagnostic tests and pathology services, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase an aggregate of 375,000 shares of common stock at a price of $6.75 per share and an aggregate of 255,000 pre-funded warrants to purchase common stock, at a purchase price of $6.74 per share, with $0.01 per share payable upon exercise of each pre-funded warrant, in a registered direct offering with aggregate gross proceeds of approximately $4.2 million. The offering is expected to close on or about January 6, 2017, subject to the satisfaction of customary closing conditions.
Nice beginning to 2017. It would be nice if they went to Saturday's event with something concrete under their belt, like having announced a TAP customer.
Thanks for sharing. FYI you can read the entire article (applies to any sign-in requiring WSJ article) for free if you Google the title of the article and open it from the search results.
Very true, LOL.
AGN Receives FDA Approval for NATRELLE INSPIRA SoftTouch Breast Implants
http://www.streetinsider.com/Corporate+News/Allergan+%28AGN%29+Receives+FDA+Approval+for+NATRELLE+INSPIRA+SoftTouch+Breast+Implants/12383537.html
OncoSec to Present at Investment Conferences in January
http://ir.oncosec.com/press-releases/detail/1891
Last day of tax loss selling. I don't think it will tank lower starting next week.
Happy New Year to all!
AGN – Brent Saunders's New Model Will Be Tested in 2017
https://www.bloomberg.com/gadfly/amp/articles/2016-12-30/brent-saunders-allergan-model-faces-2017-test
Brent Saunders's rise has been swift. He's risen so far, so fast, and in such an unusual way that the whole pharma industry is watching to see whether he'll fail -- or should be imitated.
About seven years ago, Saunders led the consumer health division at Schering-Plough. Now he's in the captain's chair at Allergan plc, the $66 billion pharma giant he helped build from what was once a smallish New Jersey generics company called Watson Pharmaceuticals.
If Treasury Secretary Jack Lew hadn’t killed Pfizer Inc.’s attempt to buy Allergan earlier this year, then Saunders would be CEO-in-waiting at the largest pharma company in the world.
That is correct ahab. While Mai Le's position is un-trackable as she is not connected in any way with ONCS, Pierce being chair of the scientific board and CSS still has to report his holdings with the SEC.
Also in all of Adil Daud's publications whether they are related to ONCS or something else, he discloses stock ownership in ONCS.
Hoping there's a turnaround in the stock price in 2017 with some positive announcements. GLTY too!
Jeff, he is still the Chief Scientific Strategist from a consultant capacity and chair of Scientific Advisory Board if you check out his LinkedIn and the company website as well.
I think when he was updating his LinkedIn profile recently he might have accidentally put an end date on his OncoSec job description but it now says "June 2016 - present."
JAZZ, MDCO, SHPG – Three Pharma Picks for Faster Drug Approvals
http://www.barrons.com/articles/three-pharma-picks-for-faster-drug-approvals-1482855610
Guggenheim Securities
We hosted meetings with Steve Pearson, the Founder and President of the Institute for Clinical and Economic Review (ICER) on Dec. 15 to discuss what changes to expect in pharmaceuticals under the Trump administration.
Pearson thinks drugs with narrower indications will be approved faster. This is positive for companies we cover such as Jazz Pharmaceuticals (ticker: JAZZ), Medicines (MDCO) and Shire (SHPG).
Pearson believes that drug pricing will continue to be a headline risk for companies with pharmacy benefit managers (PBMs) under the most pressure to prove their value. This could be a headwind for companies we cover such as Valeant Pharmaceuticals International (VRX), Mallinckrodt (MNK), Endo International (ENDP) and Horizon Pharma (HZNP).
Pearson’s ICER is not aware of any initiatives to accelerate the introduction of biosimilars into the U.S. market to lower drug spending. This would have been a positive for generics companies we cover such as Teva Pharmaceutical Industries (TEVA) and Mylan (MYL).
The Food and Drug Administration is focusing more on innovation and the 21st Century Cures Act further strengthens this objective. Pearson thinks this means it will be easier to get new drugs approved. He also thinks that pharmaceutical companies will try to get drugs approved first with a narrower indication and then expand the drug labels. This is because the FDA may allow drugs with narrower indications onto the market faster with less clinical evidence. There is also another benefit to this which is that drug companies can anchor to a higher price for a narrower indication and this will carry over into the larger indications later.
Five 'Big Idea' Biotech Trends to Watch in 2017
http://www.forbes.com/sites/luketimmerman/2016/12/27/five-big-idea-biotech-trends-to-watch-in-2017/#32077cac5d4a
What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
https://www.thestreet.com/story/13935497/1/what-adam-feuerstein-got-right-and-wrong-about-biotech-stock-in-2016.html
MRK to fall more than 20% next year as its drug patents expire - Jefferies
http://www.cnbc.com/2016/12/19/merck-to-fall-more-than-20-percent-next-year-as-its-drug-patents-expire-jefferies-says.html
Jefferies lowered its rating for Merck to underperform from hold, saying the company's financial results will be weaker than expected in coming years as its drugs lose out to generic competitors.
"Merck & Co. arguably has one of the most challenging patent expiry schedules ahead of it in the near to mid term out of the whole large cap pharma group," analyst Jeffrey Holford wrote in a note to clients Monday. "Patent expiries ... led us to lower our revenue and EPS estimates for Merck & Co. well below consensus in this update."
Holford lowered his Merck price target to $48 from $59, representing 23 percent downside from Friday's close.